{"denoms":[{"counts":[{"groupId":"BG000","value":"38"}],"units":"Participants"}],"groups":[{"description":"Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin, Cyclophosphamide: Bortezomib 1.3 mg/m2 days 1, 4, 8, 11 (initial cycles) Dexamethasone 40 mg Days 1-4, 8-11, 15-18 (initial cycles) Doxil 30 mg/m2 Day 4 of subsequent cycles","id":"BG000","title":"Treatment Arm (All Patients)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"27","upperLimit":"76","value":"61"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34"}]}],"title":"Age <70 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Age > or = 70"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"21"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"34"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"26"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1.0","upperLimit":"10.2","value":"2.05"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Beta-2 Microglubilin","unitOfMeasure":"mg/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2.0","upperLimit":"4.3","value":"3.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Serum Albumin","unitOfMeasure":"g/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"1a"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"2a"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"3a"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"3b"}],"description":"The Durie Salmon Staging System was used to assess patients status. Stage 1A is associated with a better outcome \\& a low tumor burden, stage 2A with a intermediate outcome and tumor burden, and stage 3A with a worse outcome \\& higher tumor burden. Criteria for staging is based on multiple factors including hematology values, disease burden, and renal function. The staging system can be found here: https://www.themmrf.org/multiple-myeloma/prognosis/myeloma-stages/durie-salmon-staging-system/ As assessed by the treating physician, the 1a subject:had active myeloma based on the IMWG criteria.","paramType":"NUMBER","title":"Durie Salmon Staging System","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}],"title":"I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"III"}],"description":"Measure Description: Stage I ß2-M \\< 3.5 mg/dL and albumin =3.5 g/dL Stage II Neither stage I nor stage III Stage III ß2-M ≥ 5.5 mg/L","paramType":"NUMBER","title":"International Staging System","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"trisomy 11"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"hyperdiploidy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"t (4;14)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"p53"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"del (17p)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"t (11;14)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"t (14;16)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"none"}],"description":"Cytogenetic abnormalities were assessed in patients using fluorescence in situ hybridization (FISH), which detects chromosomal abnormalities. Del (17p), t(4;14), and t (14;16) were considered High Risk cytogenetic abnormalities. All other abnormalities were considered standard risk cytogenetics.","paramType":"NUMBER","title":"Abnormalities by FISH","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"title":"lenalidomide + dexamethasone ± BIAXIN"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Thalidomide + lenalidomide + dexamethasone± BIAXIN"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Thalidomide + dexamethasone"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"thalidomide only"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"pulsed dexamethasone only"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"melphalan + cyclophosphamide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"dexamethasone, then single-agent lenalidomide"}],"paramType":"NUMBER","title":"Prior induction therapy","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"title":"partial Response"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Stable Disease"}],"description":"Best response was noted using the International Myeloma Working Group Guidelines: http://imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/","paramType":"NUMBER","title":"Best response prior to induction therapy","unitOfMeasure":"participants"}]}